Mr. Liam Woods:

The clinical evidence base clearly is international and it is internationally available. The information that would drive some of the considerations around particular drugs is also available. Through research and, particularly in this area, through the ERNs, that kind of information would be available as a backdrop against which decisions around pricing and access to market could be considered.

To the Deputy's wider point, there is co-operation already. The European Union-funded research programmes, including the one to which the Chair referred, are available for us and other European partners to bid into, as it were. It is probably a matter of some regret that colleagues in the nearest jurisdiction may not have quite the same access at this stage despite, as the Deputy says, the historical connections.